Using immune therapy before surgery for recurrent glioblastoma
Official title: Neoadjuvant checkpoint blockade for recurrent glioblastoma
Funded at University of California Los Angeles · NIH-11062541 · Data updated 2026-11-12
This study is looking at how giving a special immune therapy before surgery can help patients with recurrent glioblastoma fight their tumors better, and it will compare the results to the usual treatments given after surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 1, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $493,424 |
| NIH project number | 5R01CA267726-04 |
| Project ID | NIH-11062541 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with recurrent glioblastoma who are eligible for surgical intervention.
✕Less likely to help
Patients with non-recurrent glioblastoma or those who are not candidates for surgery may not benefit from this research.
What this research studies
This research investigates the use of immune therapy, specifically PD-1 blockade, before surgery in patients with recurrent glioblastoma. The approach aims to enhance the immune response against tumor cells by administering treatment prior to surgical intervention. The study will analyze the effects of this neoadjuvant therapy on tumor gene expression and overall patient survival compared to traditional post-surgery treatments. Patients will be monitored for changes in immune activity and tumor response throughout the treatment process.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better treatment outcomes for patients with recurrent glioblastoma.
How similar studies have gone: Previous small trials have shown promising results with neoadjuvant PD-1 blockade in glioblastoma, indicating potential for this approach.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Prins, Robert M — University of California Los Angeles
- Study coordinator: Prins, Robert M
Related research
Other NIH-funded projects on the same topics.
-
Dual-hypoxia and proliferation PET biomarker for recurrent glioblastoma
A study using a special PET imaging approach to map oxygen-poor areas and cell growth in recurrent brain tumors to guide treatment decisions.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Targeting Fatty Acid Metabolism to Fight Brain Cancer (GBM)
A new treatment approach uses a repurposed drug to cut off the energy supply of glioblastoma tumors in the brain.
-
Giving immune checkpoint therapy before surgery for recurrent glioblastoma
This research gives an immune checkpoint drug before surgery to people with recurrent glioblastoma to help the immune system attack the tumor.
-
Decorin and MRI markers to predict response to anti-VEGF treatment in recurrent glioblastoma
This project looks at whether a protein called decorin and a type of MRI (diffusion MRI) can help predict which people with recurrent glioblastoma will benefit from anti-VEGF therapy like bevacizumab.
-
Investigating how decorin and MRI can improve treatment for recurrent glioblastoma
This study is looking at how a special protein and MRI scans can help doctors figure out which patients with recurring glioblastoma might benefit the most from a treatment that blocks blood vessel growth in tumors, with the goal of improving outcomes for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.